Mereo Biopharma Group Plc ADR (MREO)

$4.38 +0.03 (0.69%)
Market Cap 530.17M
Revenue (ttm) 10.00M
Net Income (ttm) -29.47M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 28,075
Avg Vol 812,584
Day's Range N/A - N/A
Shares Out 140.26M
Stochastic %K 30%
Beta 0.88
Analysts Strong Sell
Price Target $6.80

Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian ca...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 33 3023 7300
Address:
One Cavendish Place, 4th Floor, London, United Kingdom
Mjcwo
Mjcwo Oct. 25 at 7:53 PM
$MREO OCTOBER NOVEMBER SETUP Momentum building into near-term catalysts + the Q4 data window. Shorts still lurking, float is thin, and any positive headline can send this fast. Expecting to wake up to $5 soon as the rerate trade heats up. strap in. 🔥 $BYND $ASST $LMFA
1 · Reply
keypatience
keypatience Oct. 24 at 7:33 PM
$MREO
0 · Reply
brd03
brd03 Oct. 23 at 7:25 PM
$MREO SOMEDAY!!!!!!
0 · Reply
realtorstud
realtorstud Oct. 22 at 7:22 PM
$MREO I'm in!!
0 · Reply
Berakhot
Berakhot Oct. 21 at 8:55 PM
$RARE $MREO Woooot woooooot... great find OutPerformGER!
1 · Reply
Berakhot
Berakhot Oct. 21 at 8:53 PM
$MREO 10/20 Breakthru on Daily. Hitting resistance area prior to Drop. See if it holds... and continues move up.
0 · Reply
cheetohottaki
cheetohottaki Oct. 21 at 1:36 PM
$MREO
0 · Reply
ATML
ATML Oct. 21 at 1:09 PM
$MREO I see the next big resistance at the 200dma 2.33-2.34
0 · Reply
Pakin1
Pakin1 Oct. 21 at 11:49 AM
$MREO The logical thing is that it goes to 3 dollars, these prices were not normal in the action
0 · Reply
polker9
polker9 Oct. 21 at 12:07 AM
$MREO i feel its coming. Enjoy the ride.
0 · Reply
Latest News on MREO
āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2

Aug 19, 2025, 8:30 AM EDT - 2 months ago

āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2

Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights

Aug 12, 2025, 7:35 AM EDT - 2 months ago

Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights

Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI

Jul 10, 2025, 3:15 PM EDT - 3 months ago

Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

May 13, 2025, 7:30 AM EDT - 5 months ago

Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

Mar 26, 2025, 7:30 AM EDT - 7 months ago

Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

Mar 5, 2025, 7:30 AM EST - 8 months ago

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

Mereo BioPharma Provides Update on Lead Clinical Programs

Jan 12, 2025, 11:05 AM EST - 10 months ago

Mereo BioPharma Provides Update on Lead Clinical Programs

Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:30 AM EST - 10 months ago

Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points

Nov 26, 2024, 1:36 PM EST - 11 months ago

Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 12, 2024, 7:30 AM EST - 1 year ago

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference

Sep 12, 2024, 5:35 PM EDT - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market

Jun 14, 2024, 7:50 AM EDT - 1 year ago

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market

Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

May 30, 2024, 7:30 AM EDT - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 15, 2024, 4:01 PM EDT - 1 year ago

Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 7:30 AM EDT - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

Mar 14, 2024, 5:34 PM EDT - 1 year ago

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

KRRO KRYS TAK WVE

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 7:30 AM EST - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Jan 8, 2024, 7:00 AM EST - 1 year ago

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

Oct 23, 2023, 4:01 PM EDT - 2 years ago

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update

Sep 7, 2023, 7:30 AM EDT - 2 years ago

Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update

Mereo BioPharma to Present at the Jefferies Healthcare Conference

May 31, 2023, 7:00 AM EDT - 2 years ago

Mereo BioPharma to Present at the Jefferies Healthcare Conference

Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma's Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference

May 23, 2023, 1:43 PM EDT - 2 years ago

Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma's Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 8, 2023, 12:46 PM EDT - 2 years ago

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

May 5, 2023, 4:06 PM EDT - 2 years ago

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights

Mar 28, 2023, 4:30 PM EDT - 2 years ago

Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights

Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease

Mar 21, 2023, 6:30 AM EDT - 2 years ago

Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease

Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference

Feb 8, 2023, 7:00 AM EST - 2 years ago

Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference

Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency

Nov 2, 2022, 4:01 PM EDT - 3 years ago

Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency

Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management

Oct 28, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management

Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022

Oct 24, 2022, 4:30 PM EDT - 3 years ago

Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022

Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting

Oct 21, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting

Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan

Oct 18, 2022, 11:58 AM EDT - 3 years ago

Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan

Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value

Oct 18, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value

Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease

Oct 17, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease

Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders

Oct 3, 2022, 5:00 PM EDT - 3 years ago

Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders

Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five

Oct 3, 2022, 9:00 AM EDT - 3 years ago

Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five

Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board

Sep 26, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board

Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside

Sep 22, 2022, 1:45 PM EDT - 3 years ago

Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside

Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders

Sep 14, 2022, 9:00 AM EDT - 3 years ago

Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders

Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors

Sep 12, 2022, 8:00 AM EDT - 3 years ago

Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors

Mereo BioPharma Sends Letter to Rubric Capital Management

Aug 31, 2022, 7:00 AM EDT - 3 years ago

Mereo BioPharma Sends Letter to Rubric Capital Management

Why Mereo BioPharma Shares Are Jumping Today

Jun 17, 2022, 10:39 AM EDT - 3 years ago

Why Mereo BioPharma Shares Are Jumping Today

AstraZeneca weighing bid for Mereo BioPharma: report

Jun 17, 2022, 3:44 AM EDT - 3 years ago

AstraZeneca weighing bid for Mereo BioPharma: report

AZN

Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting

May 26, 2022, 5:05 PM EDT - 3 years ago

Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting

Mjcwo
Mjcwo Oct. 25 at 7:53 PM
$MREO OCTOBER NOVEMBER SETUP Momentum building into near-term catalysts + the Q4 data window. Shorts still lurking, float is thin, and any positive headline can send this fast. Expecting to wake up to $5 soon as the rerate trade heats up. strap in. 🔥 $BYND $ASST $LMFA
1 · Reply
keypatience
keypatience Oct. 24 at 7:33 PM
$MREO
0 · Reply
brd03
brd03 Oct. 23 at 7:25 PM
$MREO SOMEDAY!!!!!!
0 · Reply
realtorstud
realtorstud Oct. 22 at 7:22 PM
$MREO I'm in!!
0 · Reply
Berakhot
Berakhot Oct. 21 at 8:55 PM
$RARE $MREO Woooot woooooot... great find OutPerformGER!
1 · Reply
Berakhot
Berakhot Oct. 21 at 8:53 PM
$MREO 10/20 Breakthru on Daily. Hitting resistance area prior to Drop. See if it holds... and continues move up.
0 · Reply
cheetohottaki
cheetohottaki Oct. 21 at 1:36 PM
$MREO
0 · Reply
ATML
ATML Oct. 21 at 1:09 PM
$MREO I see the next big resistance at the 200dma 2.33-2.34
0 · Reply
Pakin1
Pakin1 Oct. 21 at 11:49 AM
$MREO The logical thing is that it goes to 3 dollars, these prices were not normal in the action
0 · Reply
polker9
polker9 Oct. 21 at 12:07 AM
$MREO i feel its coming. Enjoy the ride.
0 · Reply
ScottyDoesntKnowMeSon
ScottyDoesntKnowMeSon Oct. 20 at 10:17 PM
$MREO what is this double digit percent green? AWS goes down and bios rally?
0 · Reply
lisaparsons
lisaparsons Oct. 20 at 8:16 PM
$MREO ok what news is coming out? something is. this never moves 9 percent in a day. lets go
0 · Reply
Pakin1
Pakin1 Oct. 20 at 6:47 PM
$MREO lets go
0 · Reply
Mjcwo
Mjcwo Oct. 20 at 5:18 PM
$MREO it’s coming…..
0 · Reply
DARKP00L
DARKP00L Oct. 20 at 3:04 PM
$MREO the market is buzzing about this stock. Expect possible price changes!
0 · Reply
fvazquez
fvazquez Oct. 20 at 3:00 PM
$MREO 7.59% up. What is happening?
0 · Reply
OutperformGER
OutperformGER Oct. 19 at 2:43 PM
$RARE is hiring a Sr. Director Global medical lead - bone for OI ($MREO) https://job-boards.greenhouse.io/ultragenyxpharmaceutical/jobs/4618943005?gh_jid=4618943005&gh_src=6eqdexj45us
2 · Reply
ATML
ATML Oct. 17 at 8:03 PM
$MREO Excellent volume in the last 10 minutes. Great sign.
0 · Reply
Mjcwo
Mjcwo Oct. 16 at 11:38 PM
$NUKK $MREO $LMFA dream team, all ready to rip to unimaginable highs…countdown on.
0 · Reply
grod86
grod86 Oct. 16 at 1:28 PM
$MREO i don’t think this gets higher than $3 before results.
1 · Reply
larchwood23
larchwood23 Oct. 15 at 11:36 PM
$MREO Hopefully the data is positive, the company gets bought out immediately, and I never have to see this ticker again!
1 · Reply
lisaparsons
lisaparsons Oct. 13 at 2:15 PM
$MREO when is next earnings or catalyst guys and gals? should have sold for capital loss months ago and bought back in. but i do this and never buy back in. just want to break even!
1 · Reply